GB9319494D0 - Pharmaceutical xanthone derivatives - Google Patents

Pharmaceutical xanthone derivatives

Info

Publication number
GB9319494D0
GB9319494D0 GB939319494A GB9319494A GB9319494D0 GB 9319494 D0 GB9319494 D0 GB 9319494D0 GB 939319494 A GB939319494 A GB 939319494A GB 9319494 A GB9319494 A GB 9319494A GB 9319494 D0 GB9319494 D0 GB 9319494D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical
xanthone derivatives
xanthone
derivatives
pharmaceutical xanthone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB939319494A
Other versions
GB2269382A (en
GB2269382B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Ltd
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919106184A external-priority patent/GB9106184D0/en
Priority claimed from GB919111736A external-priority patent/GB9111736D0/en
Priority claimed from GB919116593A external-priority patent/GB9116593D0/en
Priority claimed from GB929205301A external-priority patent/GB9205301D0/en
Application filed by Xenova Ltd filed Critical Xenova Ltd
Priority to GB9319494A priority Critical patent/GB2269382B/en
Publication of GB9319494D0 publication Critical patent/GB9319494D0/en
Publication of GB2269382A publication Critical patent/GB2269382A/en
Application granted granted Critical
Publication of GB2269382B publication Critical patent/GB2269382B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid
GB9319494A 1991-03-22 1993-09-21 Pharmaceutical compounds Expired - Fee Related GB2269382B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9319494A GB2269382B (en) 1991-03-22 1993-09-21 Pharmaceutical compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB919106184A GB9106184D0 (en) 1991-03-22 1991-03-22 Pharmaceutical compound
GB919111736A GB9111736D0 (en) 1991-05-31 1991-05-31 Pharmaceutical compound
GB919116593A GB9116593D0 (en) 1991-08-01 1991-08-01 Pharmaceutical compounds
GB929205301A GB9205301D0 (en) 1992-03-11 1992-03-11 Pharmaceutical compound
PCT/GB1992/000526 WO1992016517A1 (en) 1991-03-22 1992-03-23 Pharmaceutical xanthone derivatives
GB9319494A GB2269382B (en) 1991-03-22 1993-09-21 Pharmaceutical compounds

Publications (3)

Publication Number Publication Date
GB9319494D0 true GB9319494D0 (en) 1993-12-01
GB2269382A GB2269382A (en) 1994-02-09
GB2269382B GB2269382B (en) 1995-02-08

Family

ID=27450647

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9319494A Expired - Fee Related GB2269382B (en) 1991-03-22 1993-09-21 Pharmaceutical compounds

Country Status (4)

Country Link
EP (1) EP0580609A1 (en)
JP (1) JPH06506202A (en)
GB (1) GB2269382B (en)
WO (1) WO1992016517A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018173A2 (en) * 1992-03-11 1993-09-16 Xenova Limited Cd4 binding agents and inhibitors of collagenase and protein kinase c
ES2236702T3 (en) * 1993-12-23 2005-07-16 Eli Lilly And Company INHIBITORS OF PROTEIN QUINASA C.
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
EP0850055B1 (en) 1995-09-11 2005-06-29 Osteoarthritis Sciences, Inc. Protein tyrosine kinase inhibitors for treating osteoarthritis
CN1171400A (en) * 1996-03-05 1998-01-28 武田药品工业株式会社 Xantone compounds, their production and use
CA2375275A1 (en) 1999-06-22 2000-12-28 Mount Sinai Hospital Difuropyrone derivatives
ES2294014T3 (en) 2000-07-28 2008-04-01 Dainippon Sumitomo Pharma Co., Ltd. PROMOTERS OF THE REGENERATION OF NERVES CONTAINING A SEMAPHORINE INHIBITOR AS ACTIVE INGREDIENT.
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
WO2003062440A1 (en) * 2002-01-21 2003-07-31 Sumitomo Pharmaceuticals Co., Ltd. Xanthone derivative
WO2003062243A1 (en) 2002-01-24 2003-07-31 Sumitomo Pharmaceuticals Co., Ltd. Novel compounds as semaphorin inhibitors
WO2004085418A2 (en) * 2003-03-24 2004-10-07 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as dna-pk inhibitors
JP4820170B2 (en) * 2003-12-05 2011-11-24 大日本住友製薬株式会社 Treatment or prevention agent for ischemic neuropathy
WO2015021226A1 (en) * 2013-08-07 2015-02-12 Board Of Regents, The University Of Texas System Analogs of vinaxanthone and xanthofulvin, methods of synthesis, and methods of treatments thereof

Also Published As

Publication number Publication date
JPH06506202A (en) 1994-07-14
GB2269382A (en) 1994-02-09
GB2269382B (en) 1995-02-08
WO1992016517A1 (en) 1992-10-01
EP0580609A1 (en) 1994-02-02

Similar Documents

Publication Publication Date Title
EP0428268A3 (en) Pharmaceutical phenylpyridone derivatives
GB9319494D0 (en) Pharmaceutical xanthone derivatives
AP9200356A0 (en) Pharmaceutical composition
GB9108080D0 (en) Pharmaceutical composition
GB9114950D0 (en) Pharmaceutical formulation
HU9201971D0 (en) Chromane derivatives
GB9102727D0 (en) Pharmaceutical agent
IL101000A0 (en) Immunopotentiating drug
GB2252497B (en) Pharmaceutical composition
GB9111477D0 (en) Pharmaceutical composition
GB2271930B (en) Pharmaceutical piperazine derivatives
GB9126065D0 (en) Pharmaceutical packaging
GB9104124D0 (en) Pharmaceutical agent
GB9104123D0 (en) Pharmaceutical agent
ZA921316B (en) Immunopotentiating drug
GB9108742D0 (en) Pharmaceutical compounds
GB9121358D0 (en) Pharmaceutical compounds
GB9124439D0 (en) Pharmaceutical compounds
GB9116593D0 (en) Pharmaceutical compounds
GB9107486D0 (en) Pharmaceutical compounds
GB9107755D0 (en) Pharmaceutical compounds
GB9107754D0 (en) Pharmaceutical compounds
GB9127442D0 (en) Pharmaceutical compounds
GB9115398D0 (en) Solid drug form
GB9115107D0 (en) Pharmaceutical agents

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20000323